Clinical Study of Previously Untreated Patients With Malignant Melanoma

This study has been completed.
Sponsor:
Information provided by:
Clavis Pharma
ClinicalTrials.gov Identifier:
NCT00232726
First received: October 4, 2005
Last updated: July 9, 2007
Last verified: July 2007
  Purpose

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.


Condition Intervention Phase
Malignant Melanoma
Neoplasm Metastasis
Drug: CP-4055 (ELACYT)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Non-Randomised, Multicentre, Phase II Clinical Study of CP-4055 in Chemotherapy-Naïve Patients With Metastatic Malignant Melanoma

Resource links provided by NLM:


Further study details as provided by Clavis Pharma:

Primary Outcome Measures:
  • Objective tumour response

Secondary Outcome Measures:
  • Time to progression
  • Duration of tumour response
  • Safety and tolerability of treatment

Estimated Enrollment: 42
Study Start Date: September 2005
Study Completion Date: July 2007
Detailed Description:

This is an international multicentre phase II clinical study conducted in the USA and Europe. Previously untreated patients over 18 years, with metastatic malignant melanoma are eligible for inclusion if they fulfil all inclusion- and exclusion criteria. 16 or 42 patients will be enrolled in Pittsburgh USA, Lund Sweden and Oslo Norway.

The new development drug CP-4055 is administered for five consecutive days (Day 1 to 5) in a 4 week schedule (one cycle). The dose is 200 mg/m2/day.

A patient will continue treatment until complete response or until (s)he is withdrawn from the Clinical Study because of disease progression, unacceptable toxicity or any other reason described in the clinical study protocol.

Efficacy is assessed at baseline and end of every second cycle with CT or MRI.

Safety assessments are done at each visit. Blood samples are taken and haematological and biochemical parameters are assessed for safety.

Any adverse events are recorded and reported.

The clinical study has been approved by the relevant Independent Ethical Committees/Institutional Review Boards and Concerned Regulatory Authority as appropriate. It is conducted according to ICH Good Clinical Practice, the Declaration of Helsinki, and applicable national law and regulations.

Patients who give an additional consent will have two additional, and not mandatory, procedures performed:

  • Biopsy (tissue sample) from particular tumours (taken only at baseline for identification of tumour genes)
  • Serum samples (from blood drawn at baseline and at end of the cycle 2 for protein sequences analyses, proteomics)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-naïve)
  • Measurable disease according to Response Criteria in Solid Tumours (RECIST)
  • Performance Status 0 – 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status
  • Age 18 years or more
  • Life expectancy > 3 months
  • Signed informed consent
  • Adequate haematological and biological functions:

    • Bone marrow function:

      1. Neutrophils ≥ 1.5 x 10^9/L
      2. Platelets ≥ 100 x 10^9/L
      3. Hemoglobin (Hb) ≥ 10 g/dL
    • Hepatic function:

      1. AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN). If liver metastases, ≤ 5 times institutional ULN.
      2. Serum bilirubin and alkaline phosphatase ≤ 1.5 times institutional ULN
    • Renal function:

      • Creatinine ≤ 1.5 times institutional ULN

Exclusion Criteria:

  • Known brain metastases
  • Diagnosis of ocular malignant melanoma
  • Radiotherapy to more than 30% of bone marrow
  • Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study
  • Prior immunotherapy and/or chemotherapy for the treatment of melanoma
  • Requirement of concomitant treatment with a non-permitted medication:

    • Alternative drugs
    • High doses of vitamins
  • History of allergic reactions to Ara-C or egg
  • Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection)
  • Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient’s compliance
  • Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients
  • Known positive status for HIV and/or hepatitis B or C
  • Drug and/or alcohol abuse
  • Any reason why, in the Investigator’s opinion, the patient should not participate
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00232726

Locations
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213-2584
Norway
The Norwegian Radium Hospital
Oslo, Norway, NO-0310
Sweden
University Hospital
Lund, Sweden, SE-221 85
Sponsors and Collaborators
Clavis Pharma
Investigators
Principal Investigator: Svein Dueland, MD, Ph.D The Norwegian Radium Hospital, Montebello, NO-0310 Oslo, Norway
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00232726     History of Changes
Other Study ID Numbers: CP4055-201
Study First Received: October 4, 2005
Last Updated: July 9, 2007
Health Authority: Norway: Norwegian Medicines Agency
United States: Food and Drug Administration
Sweden: Medical Products Agency

Keywords provided by Clavis Pharma:
Malignant melanoma
CP-4055
Chemotherapy-naïve patients
Phase II
Chemotherapy-naive patients
Metastatic malignant melanoma

Additional relevant MeSH terms:
Neoplasms
Melanoma
Neoplasm Metastasis
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on April 23, 2014